Questcor (NASDAQ: QCOR) is a smaller player in the biotech space that has garnered a lot of attention on In this video, Motley Fool health-care bureau chief Brenton Flynn talks about his recent look through the SEC filings of this company, and some of the less-reported information that he found. One play the company is making: a move toward pushing for another indication, rheumatology, which the company is already moving a sales force behind.

Brenton Flynn, Max Macaluso, and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.